Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 7/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278753 | 0.90 | SPR (0.53) | NAMPTSPRHPGDMGLLPADI4 | |
| SCHEMBL2286262 | 0.88 | NAMPT (0.50) | NAMPTSPRHPGDPADI4 | |
| SCHEMBL2283196 | 0.85 | NAMPT (0.56) | NAMPTSPRPADI4PROKR1HSD11B1 | |
| SCHEMBL2283237 | 0.84 | SPR (0.52) | NAMPTSPRHPGDPADI4PROKR1 | |
| SCHEMBL2285726 | 0.84 | MGLL (0.61) | NAMPTSPRHPGDMGLLPADI4 | |
| SCHEMBL2285457 | 0.82 | NAMPT (0.49) | NAMPTSPRHPGDPADI4 | |
| SCHEMBL2281899 | 0.81 | HPGD (0.44) | NAMPTHPGD | |
| SCHEMBL2277793 | 0.81 | NAMPT (0.48) | NAMPTSPRHPGDPADI4 | |
| SCHEMBL2282198 | 0.81 | NAMPT (0.48) | NAMPTSPRHPGDMGLL | |
| SCHEMBL2280200 | 0.79 | NAMPT (0.58) | NAMPTSPRHPGDMGLLPADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | NAMPT 1938/4885SPR 3835/4885HPGD 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.